5,008 results on '"Vera J"'
Search Results
2. Pre-treatment peripheral blood immunophenotyping and response to neoadjuvant chemotherapy in operable breast cancer
- Author
-
Roberto A. Leon-Ferre, Kaitlyn R. Whitaker, Vera J. Suman, Tanya Hoskin, Karthik V. Giridhar, Raymond M. Moore, Ahmad Al-Jarrad, Sarah A. McLaughlin, Donald W. Northfelt, Katie N. Hunt, Amy Lynn Conners, Ann Moyer, Jodi M. Carter, Krishna Kalari, Richard Weinshilboum, Liewei Wang, James N. Ingle, Keith L. Knutson, Stephen M. Ansell, Judy C. Boughey, Matthew P. Goetz, and Jose C. Villasboas
- Subjects
Breast cancer ,Immunology ,Biomarkers ,Chemotherapy ,Translational research ,Single cell technologies ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background Tumor immune infiltration and peripheral blood immune signatures have prognostic and predictive value in breast cancer. Whether distinct peripheral blood immune phenotypes are associated with response to neoadjuvant chemotherapy (NAC) remains understudied. Methods Peripheral blood mononuclear cells from 126 breast cancer patients enrolled in a prospective clinical trial (NCT02022202) were analyzed using Cytometry by time-of-flight with a panel of 29 immune cell surface protein markers. Kruskal–Wallis tests or Wilcoxon rank-sum tests were used to evaluate differences in immune cell subpopulations according to breast cancer subtype and response to NAC. Results There were 122 evaluable samples: 47 (38.5%) from patients with hormone receptor-positive, 39 (32%) triple-negative (TNBC), and 36 (29.5%) HER2-positive breast cancer. The relative abundances of pre-treatment peripheral blood T, B, myeloid, NK, and unclassified cells did not differ according to breast cancer subtype. In TNBC, higher pre-treatment myeloid cells were associated with lower pathologic complete response (pCR) rates. In hormone receptor-positive breast cancer, lower pre-treatment CD8 + naïve and CD4 + effector memory cells re-expressing CD45RA (TEMRA) T cells were associated with more extensive residual disease after NAC. In HER2 + breast cancer, the peripheral blood immune phenotype did not differ according to NAC response. Conclusions Pre-treatment peripheral blood immune cell populations (myeloid in TNBC; CD8 + naïve T cells and CD4 + TEMRA cells in luminal breast cancer) were associated with response to NAC in early-stage TNBC and hormone receptor-positive breast cancers, but not in HER2 + breast cancer. Trial registration NCT02022202 . Registered 20 December 2013.
- Published
- 2024
- Full Text
- View/download PDF
3. Targeting TAG-72 in cutaneous T cell lymphomaStatement of translational relevance
- Author
-
Vera J. Evtimov, Maree V. Hammett, Aleta Pupovac, Nhu-Y N. Nguyen, Runzhe Shu, Carrie Van Der Weyden, Robert Twigger, Ian T. Nisbet, Alan O. Trounson, Richard L. Boyd, and H. Miles Prince
- Subjects
CAR-T cells ,CTCL ,TAG-72 ,CA 72-4 ,Science (General) ,Q1-390 ,Social sciences (General) ,H1-99 - Abstract
Purpose: Current monoclonal antibody-based treatment approaches for cutaneous T cell lymphoma (CTCL) rely heavily on the ability to identify a tumor specific target that is essentially absent on normal cells. Herein, we propose tumor associated glycoprotein-72 (TAG-72) as one such target. TAG-72 is a mucin-associated, truncated O-glycan that has been identified as a chimeric antigen receptor (CAR)-T cell target in solid tumor indications. To date, TAG-72 targeting has not been considered in the setting of hematological malignancies. Experimental design: CD3+ cells from patients with CTCL were analyzed for TAG-72 expression by flow cytometry. Immunohistochemistry was used to assess TAG-72 expression in CTCL patient skin lesions and a TAG-72 ELISA was employed to assess soluble TAG-72 (CA 72-4) in patient plasma. TAG-72 CAR transduction was performed on healthy donor (HD) and CTCL T cells and characterized by flow cytometry. In vitro CAR-T cell function was assessed by flow cytometry and xCELLigence® using patient peripheral blood mononuclear cells and proof-of-concept ovarian cancer cell lines. In vivo CAR-T cell function was assessed in a proof-of-concept, TAG-72+ ovarian cancer xenograft mouse model. Results: TAG-72 expression was significantly higher on total CD3+ T cells and CD4+ subsets in CTCL donors across disease stages, compared to that of HDs. TAG-72 was also present in CTCL patient skin lesions, whereas CA 72-4 was detected at low levels in both CTCL patient and HD plasma with no differences between the two groups. In vitro cytotoxicity assays showed that anti-TAG-72 CAR-T cells significantly, and specifically reduced CD3+TAG-72+ expressing CTCL cells, compared to culture with unedited T cells (no CAR). CTCL CAR-T cells had comparable function to HD CAR-T cells in vitro and CAR-T cells derived from CTCL patients eradicated cancer cells in vivo. Conclusion: This study shows the first evidence of TAG-72 as a possible target for the treatment of CTCL.
- Published
- 2024
- Full Text
- View/download PDF
4. Automated mitotic spindle hotspot counts are highly associated with clinical outcomes in systemically untreated early-stage triple-negative breast cancer
- Author
-
Roberto A. Leon-Ferre, Jodi M. Carter, David Zahrieh, Jason P. Sinnwell, Roberto Salgado, Vera J. Suman, David W. Hillman, Judy C. Boughey, Krishna R. Kalari, Fergus J. Couch, James N. Ingle, Maschenka Balkenhol, Francesco Ciompi, Jeroen van der Laak, and Matthew P. Goetz
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Operable triple-negative breast cancer (TNBC) has a higher risk of recurrence and death compared to other subtypes. Tumor size and nodal status are the primary clinical factors used to guide systemic treatment, while biomarkers of proliferation have not demonstrated value. Recent studies suggest that subsets of TNBC have a favorable prognosis, even without systemic therapy. We evaluated the association of fully automated mitotic spindle hotspot (AMSH) counts with recurrence-free (RFS) and overall survival (OS) in two separate cohorts of patients with early-stage TNBC who did not receive systemic therapy. AMSH counts were obtained from areas with the highest mitotic density in digitized whole slide images processed with a convolutional neural network trained to detect mitoses. In 140 patients from the Mayo Clinic TNBC cohort, AMSH counts were significantly associated with RFS and OS in a multivariable model controlling for nodal status, tumor size, and tumor-infiltrating lymphocytes (TILs) (p
- Published
- 2024
- Full Text
- View/download PDF
5. Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for high-risk operable Stage III melanoma: the Phase II NeoACTIVATE trial
- Author
-
Tina J. Hieken, Garth D. Nelson, Thomas J. Flotte, Eric P. Grewal, Jun Chen, Robert R. McWilliams, Lisa A. Kottschade, Lu Yang, Evidio Domingo-Musibay, Roxana S. Dronca, Yiyi Yan, Svetomir N. Markovic, Anastasios Dimou, Heather N. Montane, Courtney L. Erskine, Mara A. Piltin, Daniel L. Price, Samir S. Khariwala, Jane Hui, Carrie A. Strand, Susan M. Harrington, Vera J. Suman, Haidong Dong, and Matthew S. Block
- Subjects
Science - Abstract
Abstract Both targeted therapies and immunotherapies provide benefit in resected Stage III melanoma. We hypothesized that the combination of targeted and immunotherapy given prior to therapeutic lymph node dissection (TLND) would be tolerable and drive robust pathologic responses. In NeoACTIVATE (NCT03554083), a Phase II trial, patients with clinically evident resectable Stage III melanoma received either 12 weeks of neoadjuvant vemurafenib, cobimetinib, and atezolizumab (BRAF-mutated, Cohort A, n = 15), or cobimetinib and atezolizumab (BRAF-wild-type, Cohort B, n = 15) followed by TLND and 24 weeks of adjuvant atezolizumab. Here, we report outcomes from the neoadjuvant portion of the trial. Based on intent to treat analysis, pathologic response (≤50% viable tumor) and major pathologic response (complete or near-complete, ≤10% viable tumor) were observed in 86.7% and 66.7% of BRAF-mutated and 53.3% and 33.3% of BRAF-wild-type patients, respectively (primary outcome); these exceeded pre-specified benchmarks of 50% and 30% for major pathologic response. Grade 3 and higher toxicities, primarily dermatologic, occurred in 63% during neoadjuvant treatment (secondary outcome). No surgical delays nor progression to regional unresectability occurred (secondary outcome). Peripheral blood CD8 + TCM cell expansion associated with favorable pathologic responses (exploratory outcome).
- Published
- 2024
- Full Text
- View/download PDF
6. Integration of multiomics data shows down regulation of mismatch repair and tubulin pathways in triple-negative chemotherapy-resistant breast tumors
- Author
-
Xiaojia Tang, Kevin J. Thompson, Krishna R. Kalari, Jason P. Sinnwell, Vera J. Suman, Peter T. Vedell, Sarah A. McLaughlin, Donald W. Northfelt, Alvaro Moreno Aspitia, Richard J. Gray, Jodi M. Carter, Richard Weinshilboum, Liewei Wang, Judy C. Boughey, and Matthew P. Goetz
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype. Patients with TNBC are primarily treated with neoadjuvant chemotherapy (NAC). The response to NAC is prognostic, with reductions in overall survival and disease-free survival rates in those patients who do not achieve a pathological complete response (pCR). Based on this premise, we hypothesized that paired analysis of primary and residual TNBC tumors following NAC could identify unique biomarkers associated with post-NAC recurrence. Methods and results We investigated 24 samples from 12 non-LAR TNBC patients with paired pre- and post-NAC data, including four patients with recurrence shortly after surgery ( 48 months). These tumors were collected from a prospective NAC breast cancer study (BEAUTY) conducted at the Mayo Clinic. Differential expression analysis of pre-NAC biopsies showed minimal gene expression differences between early recurrent and nonrecurrent TNBC tumors; however, post-NAC samples demonstrated significant alterations in expression patterns in response to intervention. Topological-level differences associated with early recurrence were implicated in 251 gene sets, and an independent assessment of microarray gene expression data from the 9 paired non-LAR samples available in the NAC I-SPY1 trial confirmed 56 gene sets. Within these 56 gene sets, 113 genes were observed to be differentially expressed in the I-SPY1 and BEAUTY post-NAC studies. An independent (n = 392) breast cancer dataset with relapse-free survival (RFS) data was used to refine our gene list to a 17-gene signature. A threefold cross-validation analysis of the gene signature with the combined BEAUTY and I-SPY1 data yielded an average AUC of 0.88 for six machine-learning models. Due to the limited number of studies with pre- and post-NAC TNBC tumor data, further validation of the signature is needed. Conclusion Analysis of multiomics data from post-NAC TNBC chemoresistant tumors showed down regulation of mismatch repair and tubulin pathways. Additionally, we identified a 17-gene signature in TNBC associated with post-NAC recurrence enriched with down-regulated immune genes.
- Published
- 2023
- Full Text
- View/download PDF
7. High efficiency preparation of monodisperse plasma membrane derived extracellular vesicles for therapeutic applications
- Author
-
Claudio L. Alter, Pascal Detampel, Roman B. Schefer, Claudia Lotter, Patrick Hauswirth, Ramya D. Puligilla, Vera J. Weibel, Susanne H. Schenk, Wolf Heusermann, Melanie Schürz, Nicole Meisner-Kober, Cornelia Palivan, Tomaž Einfalt, and Jörg Huwyler
- Subjects
Biology (General) ,QH301-705.5 - Abstract
Abstract Extracellular vesicles (EVs) are highly interesting for the design of next-generation therapeutics. However, their preparation methods face challenges in standardization, yield, and reproducibility. Here, we describe a highly efficient and reproducible EV preparation method for monodisperse nano plasma membrane vesicles (nPMVs), which yields 10 to 100 times more particles per cell and hour than conventional EV preparation methods. nPMVs are produced by homogenizing giant plasma membrane vesicles following cell membrane blebbing and apoptotic body secretion induced by chemical stressors. nPMVs showed no significant differences compared to native EVs from the same cell line in cryo-TEM analysis, in vitro cellular interactions, and in vivo biodistribution studies in zebrafish larvae. Proteomics and lipidomics, on the other hand, suggested substantial differences consistent with the divergent origin of these two EV types and indicated that nPMVs primarily derive from apoptotic extracellular vesicles. nPMVs may provide an attractive source for developing EV-based pharmaceutical therapeutics.
- Published
- 2023
- Full Text
- View/download PDF
8. Digital endpoints in clinical trials of Alzheimer’s disease and other neurodegenerative diseases: challenges and opportunities
- Author
-
Anna-Katharine Brem, Sajini Kuruppu, Casper de Boer, Marijn Muurling, Ana Diaz-Ponce, Dianne Gove, Jelena Curcic, Andrea Pilotto, Wan-Fai Ng, Nicholas Cummins, Kristina Malzbender, Vera J. M. Nies, Gul Erdemli, Johanna Graeber, Vaibhav A. Narayan, Lynn Rochester, Walter Maetzler, and Dag Aarsland
- Subjects
Alzheimer’s disease ,Parkinson’s disease ,Huntington’s disease ,neurodegenerative diseases ,dementia ,digital biomarker ,Neurology. Diseases of the nervous system ,RC346-429 - Abstract
Alzheimer’s disease (AD) and other neurodegenerative diseases such as Parkinson’s disease (PD) and Huntington’s disease (HD) are associated with progressive cognitive, motor, affective and consequently functional decline considerably affecting Activities of Daily Living (ADL) and quality of life. Standard assessments, such as questionnaires and interviews, cognitive testing, and mobility assessments, lack sensitivity, especially in early stages of neurodegenerative diseases and in the disease progression, and have therefore a limited utility as outcome measurements in clinical trials. Major advances in the last decade in digital technologies have opened a window of opportunity to introduce digital endpoints into clinical trials that can reform the assessment and tracking of neurodegenerative symptoms. The Innovative Health Initiative (IMI)-funded projects RADAR-AD (Remote assessment of disease and relapse—Alzheimer’s disease), IDEA-FAST (Identifying digital endpoints to assess fatigue, sleep and ADL in neurodegenerative disorders and immune-mediated inflammatory diseases) and Mobilise-D (Connecting digital mobility assessment to clinical outcomes for regulatory and clinical endorsement) aim to identify digital endpoints relevant for neurodegenerative diseases that provide reliable, objective, and sensitive evaluation of disability and health-related quality of life. In this article, we will draw from the findings and experiences of the different IMI projects in discussing (1) the value of remote technologies to assess neurodegenerative diseases; (2) feasibility, acceptability and usability of digital assessments; (3) challenges related to the use of digital tools; (4) public involvement and the implementation of patient advisory boards; (5) regulatory learnings; and (6) the significance of inter-project exchange and data- and algorithm-sharing.
- Published
- 2023
- Full Text
- View/download PDF
9. Electroconvulsive therapy triggers a reversible decrease in brain N-acetylaspartate
- Author
-
Vera J. Erchinger, Alexander R. Craven, Lars Ersland, Ketil J. Oedegaard, Christoffer A. Bartz-Johannessen, Åsa Hammar, Jan Haavik, Frank Riemer, Ute Kessler, and Leif Oltedal
- Subjects
depression ,electroconvulsive therapy ,1H-MRS nuclear magnetic resonance spectroscopy ,neurometabolites ,choline ,myoinositol ,Psychiatry ,RC435-571 - Abstract
IntroductionBased on previous research on electroconvulsive therapy (ECT) we have proposed a model where disruption, potentiation, and rewiring of brain networks occur in sequence and serve as the underlying therapeutic mechanism of ECT. This model implies that a temporary disturbance of neuronal networks (disruption) is followed by a trophic effect (potentiation), which enables the rewiring of neuronal circuits to a more euthymic functioning brain. We hypothesized that disruption of neuronal networks could trigger biochemical alterations leading to a temporary decrease in N-acetylaspartate (tNAA, considered a marker of neuronal integrity), while choline (a membrane component), myo-Inositol (mI, astroglia marker), and glutamate/glutamine (Glx, excitatory neurotransmitter) were postulated to increase. Previous magnetic resonance spectroscopy studies, reporting diverse findings, have used two different referencing methods - creatine ratios and tissue corrected values referenced to water – for the quantification of brain metabolites. Changes in creatine during ECT have also been reported, which may confound estimates adopting this as an internal reference.MethodsUsing MR spectroscopy, we investigated 31 moderately to severely depressed patients and 19 healthy controls before, during, and after ECT or at similar time points (for controls). We tested whether biochemical alterations in tNAA, choline, mI, and Glx lend support to the disrupt, potentiate, and rewire hypothesis. We used both creatine ratios and water-scaled values for the quantification of brain metabolites to validate the results across referencing methods.ResultsLevels of tNAA in the anterior cingulate cortex decreased after an ECT treatment series (average 10.6 sessions) by 6% (p = 0.007, creatine ratio) and 3% (p = 0.02, water referenced) but returned to baseline 6 months after ECT. Compared to after treatment series tNAA levels at 6-month follow-up had increased in both creatine ratio (+6%, p
- Published
- 2023
- Full Text
- View/download PDF
10. Field of creative culture: a study of creative movement and innovation of terracotta culture in Jatiwangi, Indonesia
- Author
-
Agus S. Ekomadyo, Nurrohman Wijaya, Vera J. Vardhani, Annas T. Maulana, Hernadi Suhendar, and Vanessa Susanto
- Subjects
creative city ,creative culture ,cultural capital ,field of creativity ,innovation ,Jatiwangi ,Social sciences (General) ,H1-99 - Abstract
Although the creative city concept has received much criticism, the creative movement still occurs to fight for a better city. The decline in the terracotta tile business in Jatiwangi, Majalengka Regency, West Java, Indonesia, has triggered a creative movement to revitalize their identity through the Terracotta City movement. By combining Mihaly Csikszentmihalyi’s field of creativity and Pierre Bourdieu’s cultural capital, this study is carried out to reveal the creative culture of terracotta tile entrepreneurs in Jatiwangi and its relation to the movement. It is found that entrepreneurs’ creative culture is dominantly stimulated by economic capital, and then it is transformed into cultural capital. Innovations are only made, if the market share is clear since it bears economic risks. However, social capital has a role in transforming entrepreneurs’ economic and cultural capital to accept innovation and product diversification. This study also reveals that entrepreneurs as adopters intend to initiate innovation and diversification of terracotta products. However, within the framework of innovation, it shows that creative culture plays a role in incorporating aspects of humanity into innovation activities by giving innovation efforts to represent human beings.
- Published
- 2023
- Full Text
- View/download PDF
11. Estrogen receptor beta repurposes EZH2 to suppress oncogenic NFκB/p65 signaling in triple negative breast cancer
- Author
-
Kirsten G. M. Aspros, Jodi M. Carter, Tanya L. Hoskin, Vera J. Suman, Malayannan Subramaniam, Michael J. Emch, Zhenqing Ye, Zhifu Sun, Jason P. Sinnwell, Kevin J. Thompson, Xiaojia Tang, Esther P. B. Rodman, Xiyin Wang, Adam W. Nelson, Igor Chernukhin, Feda H. Hamdan, Elizabeth S. Bruinsma, Jason S. Carroll, Martin E. Fernandez-Zapico, Steven A. Johnsen, Krishna R. Kalari, Haojie Huang, Roberto A. Leon-Ferre, Fergus J. Couch, James N. Ingle, Matthew P. Goetz, and John R. Hawse
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Triple Negative Breast Cancer (TNBC) accounts for 15–20% of all breast cancer cases, yet is responsible for a disproportionately high percentage of breast cancer mortalities. Thus, there is an urgent need to identify novel biomarkers and therapeutic targets based on the molecular events driving TNBC pathobiology. Estrogen receptor beta (ERβ) is known to elicit anti-cancer effects in TNBC, however its mechanisms of action remain elusive. Here, we report the expression profiles of ERβ and its association with clinicopathological features and patient outcomes in the largest cohort of TNBC to date. In this cohort, ERβ was expressed in approximately 18% of TNBCs, and expression of ERβ was associated with favorable clinicopathological features, but correlated with different overall survival outcomes according to menopausal status. Mechanistically, ERβ formed a co-repressor complex involving enhancer of zeste homologue 2/polycomb repressive complex 2 (EZH2/PRC2) that functioned to suppress oncogenic NFκB/RELA (p65) activity. Importantly, p65 was shown to be required for formation of this complex and for ERβ-mediated suppression of TNBC. Our findings indicate that ERβ+ tumors exhibit different characteristics compared to ERβ− tumors and demonstrate that ERβ functions as a molecular switch for EZH2, repurposing it for tumor suppressive activities and repression of oncogenic p65 signaling.
- Published
- 2022
- Full Text
- View/download PDF
12. Ubiquitin variants potently inhibit SARS-CoV-2 PLpro and viral replication via a novel site distal to the protease active site.
- Author
-
Vera J E van Vliet, Nhan Huynh, Judith Palà, Ankoor Patel, Alex Singer, Cole Slater, Jacky Chung, Mariska van Huizen, Joan Teyra, Shane Miersch, Gia-Khanh Luu, Wei Ye, Nitin Sharma, Safder S Ganaie, Raquel Russell, Chao Chen, Mindy Maynard, Gaya K Amarasinghe, Brian L Mark, Marjolein Kikkert, and Sachdev S Sidhu
- Subjects
Immunologic diseases. Allergy ,RC581-607 ,Biology (General) ,QH301-705.5 - Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has made it clear that combating coronavirus outbreaks benefits from a combination of vaccines and therapeutics. A promising drug target common to all coronaviruses-including SARS-CoV, MERS-CoV, and SARS-CoV-2-is the papain-like protease (PLpro). PLpro cleaves part of the viral replicase polyproteins into non-structural protein subunits, which are essential to the viral replication cycle. Additionally, PLpro can cleave both ubiquitin and the ubiquitin-like protein ISG15 from host cell substrates as a mechanism to evade innate immune responses during infection. These roles make PLpro an attractive antiviral drug target. Here we demonstrate that ubiquitin variants (UbVs) can be selected from a phage-displayed library and used to specifically and potently block SARS-CoV-2 PLpro activity. A crystal structure of SARS-CoV-2 PLpro in complex with a representative UbV reveals a dimeric UbV bound to PLpro at a site distal to the catalytic site. Yet, the UbV inhibits the essential cleavage activities of the protease in vitro and in cells, and it reduces viral replication in cell culture by almost five orders of magnitude.
- Published
- 2022
- Full Text
- View/download PDF
13. Micro-hydrogel injectables that deliver effective CAR-T immunotherapy against 3D solid tumor spheroids
- Author
-
Anisha B. Suraiya, Vera J. Evtimov, Vinh X. Truong, Richard L. Boyd, John S. Forsythe, and Nicholas R. Boyd
- Subjects
Microgels ,Cell encapsulation ,Immunotherapy ,CAR-T cells ,Cell delivery ,Tumor spheroids ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Chimeric antigen receptor (CAR-) T cells are revolutionizing cancer treatment, as a direct result of their clinical impact on the treatment of hematological malignancies. However for solid tumors, CAR-T cell therapeutic efficacy remains limited, primarily due to the complex immunosuppressive tumor microenvironment, inefficient access to tumor cells and poor persistence of the killer cells. In this in vitro study, an injectable, gelatin-based micro-hydrogel system that can encapsulate and deliver effective CAR-T therapy is investigated. CAR-T cells targeting TAG-72, encapsulated in these microgels possessed high viability (> 87%) after 7 days, equivalent to those grown under normal expansion conditions, with retention of the T cell phenotype and functionality. Microgel recovered CAR-T cells demonstrated potent on-target cytotoxicity against human ovarian cancer in vitro and on three-dimensional tumor spheroids, by completely eliminating tumor cells. The gelatin-based micro-hydrogels have the potential to serve as carrier systems to augment CAR-T immunotherapeutic treatment of solid tumors.
- Published
- 2022
- Full Text
- View/download PDF
14. CAR-T cell development for Cutaneous T cell Lymphoma: current limitations and potential treatment strategies
- Author
-
Van To, Vera J. Evtimov, Graham Jenkin, Aleta Pupovac, Alan O. Trounson, and Richard L. Boyd
- Subjects
CAR-T cells ,CTCL ,dual CARs ,on-target/off-tumor toxicity ,tumor heterogeneity ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Chimeric antigen receptor (CAR)-T therapy has demonstrated remarkable outcomes for B cell malignancies, however, its application for T cell lymphoma, particularly cutaneous T cell lymphoma (CTCL), has been limited. Barriers to effective CAR-T cell therapy in treating CTCL include T cell aplasia in autologous transplants, CAR-T product contamination with leukemic T cells, CAR-T fratricide (when the target antigen is present on normal T cells), and tumor heterogeneity. To address these critical challenges, innovative CAR engineering by targeting multiple antigens to strike a balance between efficacy and safety of the therapy is necessary. In this review, we discuss the current obstacles to CAR-T cell therapy and highlight potential targets in treating CTCL. Looking forward, we propose strategies to develop more powerful dual CARs that are advancing towards the clinic in CTCL therapy.
- Published
- 2022
- Full Text
- View/download PDF
15. Remote monitoring technologies in Alzheimer’s disease: design of the RADAR-AD study
- Author
-
Marijn Muurling, Casper de Boer, Rouba Kozak, Dorota Religa, Ivan Koychev, Herman Verheij, Vera J. M. Nies, Alexander Duyndam, Meemansa Sood, Holger Fröhlich, Kristin Hannesdottir, Gul Erdemli, Federica Lucivero, Claire Lancaster, Chris Hinds, Thanos G. Stravopoulos, Spiros Nikolopoulos, Ioannis Kompatsiaris, Nikolay V. Manyakov, Andrew P. Owens, Vaibhav A. Narayan, Dag Aarsland, Pieter Jelle Visser, and the RADAR-AD Consortium
- Subjects
Alzheimer’s disease ,Remote monitoring technologies ,Wearable technologies ,Neurosciences. Biological psychiatry. Neuropsychiatry ,RC321-571 ,Neurology. Diseases of the nervous system ,RC346-429 - Abstract
Abstract Background Functional decline in Alzheimer’s disease (AD) is typically measured using single-time point subjective rating scales, which rely on direct observation or (caregiver) recall. Remote monitoring technologies (RMTs), such as smartphone applications, wearables, and home-based sensors, can change these periodic subjective assessments to more frequent, or even continuous, objective monitoring. The aim of the RADAR-AD study is to assess the accuracy and validity of RMTs in measuring functional decline in a real-world environment across preclinical-to-moderate stages of AD compared to standard clinical rating scales. Methods This study includes three tiers. For the main study, we will include participants (n = 220) with preclinical AD, prodromal AD, mild-to-moderate AD, and healthy controls, classified by MMSE and CDR score, from clinical sites equally distributed over 13 European countries. Participants will undergo extensive neuropsychological testing and physical examination. The RMT assessments, performed over an 8-week period, include walk tests, financial management tasks, an augmented reality game, two activity trackers, and two smartphone applications installed on the participants’ phone. In the first sub-study, fixed sensors will be installed in the homes of a representative sub-sample of 40 participants. In the second sub-study, 10 participants will stay in a smart home for 1 week. The primary outcome of this study is the difference in functional domain profiles assessed using RMTs between the four study groups. The four participant groups will be compared for each RMT outcome measure separately. Each RMT outcome will be compared to a standard clinical test which measures the same functional or cognitive domain. Finally, multivariate prediction models will be developed. Data collection and privacy are important aspects of the project, which will be managed using the RADAR-base data platform running on specifically designed biomedical research computing infrastructure. Results First results are expected to be disseminated in 2022. Conclusion Our study is well placed to evaluate the clinical utility of RMT assessments. Leveraging modern-day technology may deliver new and improved methods for accurately monitoring functional decline in all stages of AD. It is greatly anticipated that these methods could lead to objective and real-life functional endpoints with increased sensitivity to pharmacological agent signal detection.
- Published
- 2021
- Full Text
- View/download PDF
16. Engineered CAR-T cells targeting TAG-72 and CD47 in ovarian cancer
- Author
-
Runzhe Shu, Vera J. Evtimov, Maree V. Hammett, Nhu-Y N. Nguyen, Junli Zhuang, Peter J. Hudson, Maureen C. Howard, Aleta Pupovac, Alan O. Trounson, and Richard L. Boyd
- Subjects
CAR-T cells ,dual specificity ,ovarian cancer ,TAG-72 ,CD47 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Chimeric antigen receptor (CAR) T cells have revolutionized blood cancer immunotherapy; however, their efficacy against solid tumors has been limited. A common mechanism of tumor escape from single target therapies is downregulation or mutational loss of the nominal epitope. Targeting multiple antigens may thus improve the effectiveness of CAR immunotherapies. We generated dual CAR-T cells targeting two tumor antigens: TAG-72 (tumor-associated glycoprotein 72) and CD47. TAG-72 is a pan-adenocarcinoma oncofetal antigen, highly expressed in ovarian cancers, with increased expression linked to disease progression. CD47 is ubiquitously overexpressed in multiple tumor types, including ovarian cancer; it is a macrophage “don’t eat me” signal. However, CD47 is also expressed on many normal cells. To avoid this component of the dual CAR-T cells killing healthy tissue, we designed a truncated CD47 CAR devoid of intracellular signaling domains. The CD47 CAR facilitates binding to CD47+ cells, increasing the prospect of TAG-72+ cell elimination via the TAG-72 CAR. Furthermore, we could reduce the damage to normal tissue by monomerizing the CD47 CAR. Our results indicate that the co-expression of the TAG-72 CAR and the CD47-truncated monomer CAR on T cells could be an effective, dual CAR-T cell strategy for ovarian cancer, also applicable to other adenocarcinomas.
- Published
- 2021
- Full Text
- View/download PDF
17. DIAGNÓSTICO PARA LA MEJORA CONTINUA DEL SISTEMA PRODUCTIVO: REDISEÑO Y ADAPTACIÓN PARA MIPYMES
- Author
-
Jorge Alberto Oviedo Zabala and Vera J. Santiago Martínez
- Subjects
diagnóstico empresarial ,modelo de integración ,mipymes ,competitividad ,valor agregado ,mejora continua ,autodiagnóstico ,Engineering (General). Civil engineering (General) ,TA1-2040 - Abstract
El objetivo de esta investigación fue el rediseño y adaptación de una herramienta de diagnóstico del sistema productivo para su uso en micro, pequeñas y medianas empresas manufactureras. El fundamento teórico de esta investigación lo constituye el trabajo de Rajadell Carreras, formulado en 2005, a partir del cual se desarrolló un cuestionario que permite evaluar de forma preliminar el estado de una Mipyme ante un proceso de mejora continua. Las Mipymes buscan la mejora que pueda ayudarlas a lograr mayor competitividad y que les permita asegurar su supervivencia en el mercado. A lo largo del documento se presenta la base teórica de la investigación, su metodología y la herramienta de diagnóstico rediseñada y adaptada para Mipymes. Esta última consta de cincuenta preguntas relacionadas a nueve áreas que obtener una valoración de tres estados en cada una de ellas.
- Published
- 2020
- Full Text
- View/download PDF
18. Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer
- Author
-
Swaathi Jayaraman, Xiaonan Hou, Mary J. Kuffel, Vera J. Suman, Tanya L. Hoskin, Kathryn E. Reinicke, David G. Monroe, Krishna R. Kalari, Xiaojia Tang, Megan A. Zeldenrust, Jingfei Cheng, Elizabeth S. Bruinsma, Sarah A. Buhrow, Renee M. McGovern, Stephanie L. Safgren, Chad A. Walden, Jodi M. Carter, Joel M. Reid, James N. Ingle, Matthew M. Ames, John R. Hawse, and Matthew P. Goetz
- Subjects
Z-endoxifen ,Tamoxifen ,Tumor growth in vivo ,Estrogen-regulated genes ,AI-resistant and AI-sensitive ER+ breast cancer ,Signaling kinase ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background The tamoxifen metabolite, Z-endoxifen, demonstrated promising antitumor activity in endocrine-resistant estrogen receptor-positive (ER+) breast cancer. We compared the antitumor activity of Z-endoxifen with tamoxifen and letrozole in the letrozole-sensitive MCF7 aromatase expressing model (MCF7AC1), as well as with tamoxifen, fulvestrant, exemestane, and exemestane plus everolimus in a letrozole-resistant MCF7 model (MCF7LR). Methods MCF7AC1 tumor-bearing mice were randomized to control (no drug), letrozole (10 μg/day), tamoxifen (500 μg/day), or Z-endoxifen (25 and 75 mg/kg). Treatment in the letrozole arm was continued until resistance developed. MCF7LR tumor-bearing mice were then randomized to Z-endoxifen (50 mg/kg) or tamoxifen for 4 weeks and tumors harvested for microarray and immunohistochemistry analysis. The antitumor activity of Z-endoxifen in the MCF7LR tumors was further compared in a second in vivo study with exemestane, exemestane plus everolimus, and fulvestrant. Results In the MCF7AC1 tumors, both Z-endoxifen doses were significantly superior to control and tamoxifen in reducing tumor volumes at 4 weeks. Additionally, the 75 mg/kg Z-endoxifen dose was additionally superior to letrozole. Prolonged letrozole exposure resulted in resistance at 25 weeks. In MCF7LR tumor-bearing mice, Z-endoxifen significantly reduced tumor volumes compared to tamoxifen, letrozole, and exemestane, with no significant differences compared to exemestane plus everolimus and fulvestrant. Additionally, compared to tamoxifen, Z-endoxifen markedly inhibited ERα target genes, Ki67 and Akt expression in vivo. Conclusion In endocrine-sensitive and letrozole-resistant breast tumors, Z-endoxifen results in robust antitumor and antiestrogenic activity compared to tamoxifen and aromatase inhibitor monotherapy. These data support the ongoing development of Z-endoxifen.
- Published
- 2020
- Full Text
- View/download PDF
19. Human iPSC-Derived Neural Crest Stem Cells Exhibit Low Immunogenicity
- Author
-
Vera J. Mehler, Chris J. Burns, Hans Stauss, Robert J. Francis, and Melanie L. Moore
- Subjects
Genetics ,QH426-470 ,Cytology ,QH573-671 - Abstract
Recent clinical trials are evaluating induced pluripotent stem cells (iPSCs) as a cellular therapy in the field of regenerative medicine. The widespread clinical utility of iPSCs is expected to be realized using allogeneic cells that have undergone thorough safety evaluations, including assessment of their immunogenicity. IPSC-derived neural crest stem cells (NCSCs) have significant potential in regenerative medicine; however, their application in cellular therapy has not been widely studied to date, and no reports on their potential immunogenicity have been published so far. In this study, we have assessed the expression of immune-related antigens in iPSC-NCSCs, including human leukocyte antigen (HLA) class I and II and co-stimulatory molecules. To investigate functional immunogenicity, we used iPSC-NCSCs as stimulator cells in a one-way mixed lymphocyte reaction. In these experiments, iPSC-NCSCs did not stimulate detectable proliferation of CD3+ and CD3+CD8+ T cells or induce cytokine production. We show that this was not a result of any immunosuppressive features of iPSC-NCSCs, but rather more consistent with their non-immunogenic molecular phenotype. These results are encouraging for the potential future use of iPSC-NCSCs as a cellular therapy.
- Published
- 2020
- Full Text
- View/download PDF
20. Behavioral and psychological impact of returning breast density results to Latinas: study protocol for a randomized clinical trial
- Author
-
Bhavika K. Patel, Jennifer L. Ridgeway, Karthik Ghosh, Deborah J. Rhodes, Bijan Borah, Sarah Jenkins, Vera J. Suman, Aaron Norman, Matt Jewett, Davinder Singh, Celine M. Vachon, and Carmen Radecki Breitkopf
- Subjects
Mammographic breast density (MBD) ,Mammography ,Breast density ,Breast density legislation ,Breast cancer ,Hispanic ,Medicine (General) ,R5-920 - Abstract
Abstract Background Breast cancer is the most common cancer and the leading cause of cancer mortality among Latinas. As more is learned about the association between mammographic breast density (MBD) and breast cancer risk, a number of U.S. states adopted legislation and now a federal law mandates written notification of MBD along with mammogram results. These notifications vary in content and readability, though, which may limit their effectiveness and create confusion or concern, especially among women with low health literacy or barriers to screening. The purpose of this study is to determine whether educational enhancement of MBD notification results in increased knowledge, decreased anxiety, and adherence to continued mammography screening among Latina women in a limited-resources setting. Methods Latinas LEarning About Density (LLEAD) is a randomized clinical trial (RCT) comparing the impact of three notification approaches on behavioral and psychological outcomes in Latina women. Approximately 2000 Latinas undergoing screening mammography in a safety-net community clinic will be randomized 1:1:1 to mailed notification (usual care); mailed notification plus written educational materials (enhanced); or mailed notification, written educational materials, plus verbal explanation by a promotora (interpersonal). The educational materials and verbal explanations are available in Spanish or English. Mechanisms through which written or verbal information influences future screening motivation and behavior will be examined, as well as moderating factors such as depression and worry about breast cancer, which have been linked to diagnostic delays among Latinas. The study includes multiple psychological measures (anxiety, depression, knowledge about MBD, perceived risk of breast cancer, worry, self-efficacy) and behavioral outcomes (continued adherence to mammography). Measurement time points include enrollment, 2–4 weeks post-randomization, and 1 and 2 years post-randomization. Qualitative inquiry related to process and outcomes of the interpersonal arm and cost analysis related to its implementation will be undertaken to understand the intervention’s delivery and transferability. Discussion Legislation mandating written MBD notification may have unintended consequences on behavioral and psychological outcomes, particularly among Latinas with limited health literacy and resources. This study has implications for cancer risk communication and will offer evidence on the potential of generalizable educational strategies for delivering information on breast density to Latinas in limited-resource settings. Trial registration ClinicalTrials.gov, NCT02910986. Registered on 21 September 2016. Items from the WHO Trial Registration Data Set can be found in this protocol.
- Published
- 2019
- Full Text
- View/download PDF
21. Structured Data Storage for Data-Driven Process Optimisation in Bioprinting
- Author
-
Barbara Schmieg, Nico Brandt, Vera J. Schnepp, Luka Radosevic, Sarah Gretzinger, Michael Selzer, and Jürgen Hubbuch
- Subjects
bioprinting ,data-driven process development ,data filtering ,digitisation ,electronic lab notebook ,open source ,Technology ,Engineering (General). Civil engineering (General) ,TA1-2040 ,Biology (General) ,QH301-705.5 ,Physics ,QC1-999 ,Chemistry ,QD1-999 - Abstract
Bioprinting is a method to fabricate 3D models that mimic tissue. Future fields of application might be in pharmaceutical or medical context. As the number of applicants might vary between only one patient to manufacturing tissue for high-throughput drug screening, designing a process will necessitate a high degree of flexibility, robustness, as well as comprehensive monitoring. To enable quality by design process optimisation for future application, establishing systematic data storage routines suitable for automated analytical tools is highly desirable as a first step. This manuscript introduces a workflow for process design, documentation within an electronic lab notebook and monitoring to supervise the product quality over time or at different locations. Lab notes, analytical data and corresponding metadata are stored in a systematic hierarchy within the research data infrastructure Kadi4Mat, which allows for continuous, flexible data structuring and access management. To support the experimental and analytical workflow, additional features were implemented to enhance and build upon the functionality provided by Kadi4Mat, including browser-based file previews and a Python tool for the combined filtering and extraction of data. The structured research data management with Kadi4Mat enables retrospective data grouping and usage by process analytical technology tools connecting individual analysis software to machine-readable data exchange formats.
- Published
- 2022
- Full Text
- View/download PDF
22. Anterior cingulate gamma‐aminobutyric acid concentrations and electroconvulsive therapy
- Author
-
Vera J. Erchinger, Jeremy Miller, Thomas Jones, Ute Kessler, Juan Bustillo, Jan Haavik, Jonathan Petrillo, Gregory Ziomek, Åsa Hammar, Ketil J. Oedegaard, Vince D. Calhoun, Shawn M. McClintock, Lars Ersland, Leif Oltedal, and Christopher C. Abbott
- Subjects
depression ,electroconvulsive therapy ,gamma‐aminobutyric acid ,magnetic resonance spectroscopy ,Neurosciences. Biological psychiatry. Neuropsychiatry ,RC321-571 - Abstract
Abstract Objective The anticonvulsant hypothesis posits that ECT’s mechanism of action is related to enhancement of endogenous anticonvulsant brain mechanisms. Results of prior studies investigating the role of the inhibitory neurotransmitter gamma‐aminobutyric acid (“GABA+”, GABA and coedited macromolecules) in the pathophysiology and treatment of depression remain inconclusive. The aim of our study was to investigate treatment‐responsive changes of GABA+ in subjects with a depressive episode receiving electroconvulsive therapy (ECT). Methods In total, 41 depressed subjects (DEP) and 35 healthy controls (HC) were recruited at two independent sites in Norway and the USA. MEGA‐PRESS was used for investigation of GABA+ in the anterior cingulate cortex. We assessed longitudinal and cross‐sectional differences between DEP and HC, as well as the relationship between GABA+ change and change in depression severity and number of ECTs. We also assessed longitudinal differences in cognitive performance and GABA+ levels. Results Depressive episode did not show a difference in GABA+ relative to HC (t71 = −0.36, p = .72) or in longitudinal analysis (t36 = 0.97, p = .34). Remitters and nonremitters did not show longitudinal (t36 = 1.12, p = .27) or cross‐sectional differences in GABA+. GABA+ levels were not related to changes in antidepressant response (t35 = 1.12, p = .27) or treatment number (t36 = 0.05, p = .96). An association between cognitive performance and GABA+ levels was found in DEP that completed cognitive effortful testing (t18 = 2.4, p = .03). Conclusion Our results failed to support GABA as a marker for depression and abnormal mood state and provide no support for the anticonvulsant hypothesis of ECT. ECT‐induced change in GABA concentrations may be related to change in cognitive function.
- Published
- 2020
- Full Text
- View/download PDF
23. Frameworks for self-management support for chronic disease: a cross-country comparative document analysis
- Author
-
Selena O’Connell, Vera J. C. Mc Carthy, and Eileen Savage
- Subjects
Document analysis ,Health policy analysis ,Self-management support ,Chronic disease ,Public aspects of medicine ,RA1-1270 - Abstract
Abstract Background In a number of countries, frameworks have been developed to improve self-management support (SMS) in order to reduce the impact of chronic disease. The frameworks potentially provide direction for system-wide change in the provision of SMS by healthcare systems. Although policy formulation sets a foundation for health service reform, little is currently known about the processes which underpin SMS framework development as well as the respective implementation and evaluation plans. Methods The aim of this study was to conduct a cross-country comparative document analysis of frameworks on SMS for chronic diseases in member countries of the Organisation for Economic Cooperation and Development. SMS frameworks were sourced through a systematic grey literature search and compared through document analysis using the Health Policy Triangle framework focusing on policy context, contents, actors involved and processes of development, implementation and evaluation. Results Eight framework documents published from 2008 to 2017 were included for analysis from: Scotland, Wales, Ireland, Manitoba, Queensland, Western Australia, Tasmania and the Northern Territory. The number of chronic diseases identified for SMS varied across the frameworks. A notable gap was a lack of focus on multimorbidity. Common courses of action across countries included the provision of self-management programmes for individuals with chronic disease and education to health professionals, though different approaches were proposed. The ‘actors’ involved in policy formulation were inconsistent across countries and it was only clear from two frameworks that individuals with chronic disease were directly involved. Half of the frameworks had SMS implementation plans with timelines. Although all frameworks referred to the need for evaluation of SMS implementation, few provided a detailed plan. Conclusions Differences across frameworks may have implications for their success including: the extent to which people with chronic disease are involved in policy making; the courses of action taken to enhance SMS; and planned implementation processes including governance and infrastructure. Further research is needed to examine how differences in frameworks have affected implementation and to identify the critical success factors in SMS policy implementation.
- Published
- 2018
- Full Text
- View/download PDF
24. Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer study
- Author
-
Jia Yu, Bo Qin, Ann M. Moyer, Jason P. Sinnwell, Kevin J. Thompson, John A. Copland, Laura A. Marlow, James L. Miller, Ping Yin, Bowen Gao, Katherine Minter-Dykhouse, Xiaojia Tang, Sarah A. McLaughlin, Alvaro Moreno-Aspitia, Anthony Schweitzer, Yan Lu, Jason Hubbard, Donald W. Northfelt, Richard J. Gray, Katie Hunt, Amy L. Conners, Vera J. Suman, Krishna R. Kalari, James N. Ingle, Zhenkun Lou, Daniel W. Visscher, Richard Weinshilboum, Judy C. Boughey, Matthew P. Goetz, and Liewei Wang
- Subjects
Breast cancer ,Patient-derived Xenograft (PDX) ,Percutaneous tumor biopsies (PTB) ,Prospective neoadjuvant chemotherapy (NAC) ,Pre-clinical therapy ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background Patient-derived xenografts (PDXs) are increasingly used in cancer research as a tool to inform cancer biology and drug response. Most available breast cancer PDXs have been generated in the metastatic setting. However, in the setting of operable breast cancer, PDX models both sensitive and resistant to chemotherapy are needed for drug development and prospective data are lacking regarding the clinical and molecular characteristics associated with PDX take rate in this setting. Methods The Breast Cancer Genome Guided Therapy Study (BEAUTY) is a prospective neoadjuvant chemotherapy (NAC) trial of stage I-III breast cancer patients treated with neoadjuvant weekly taxane+/-trastuzumab followed by anthracycline-based chemotherapy. Using percutaneous tumor biopsies (PTB), we established and characterized PDXs from both primary (untreated) and residual (treated) tumors. Tumor take rate was defined as percent of patients with the development of at least one stably transplantable (passed at least for four generations) xenograft that was pathologically confirmed as breast cancer. Results Baseline PTB samples from 113 women were implanted with an overall take rate of 27.4% (31/113). By clinical subtype, the take rate was 51.3% (20/39) in triple negative (TN) breast cancer, 26.5% (9/34) in HER2+, 5.0% (2/40) in luminal B and 0% (0/3) in luminal A. The take rate for those with pCR did not differ from those with residual disease in TN (p = 0.999) and HER2+ (p = 0.2401) tumors. The xenografts from 28 of these 31 patients were such that at least one of the xenografts generated had the same molecular subtype as the patient. Among the 35 patients with residual tumor after NAC adequate for implantation, the take rate was 17.1%. PDX response to paclitaxel mirrored the patients’ clinical response in all eight PDX tested. Conclusions The generation of PDX models both sensitive and resistant to standard NAC is feasible and these models exhibit similar biological and drug response characteristics as the patients’ primary tumors. Taken together, these models may be useful for biomarker discovery and future drug development.
- Published
- 2017
- Full Text
- View/download PDF
25. Correction to: Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer study
- Author
-
Jia Yu, Bo Qin, Ann M. Moyer, Jason P. Sinnwell, Kevin J. Thompson, John A. Copland, Laura A. Marlow, James L. Miller, Ping Yin, Bowen Gao, Katherine Minter-Dykhouse, Xiaojia Tang, Sarah A. McLaughlin, Alvaro Moreno-Aspitia, Anthony Schweitzer, Yan Lu, Jason Hubbard, Donald W. Northfelt, Richard J. Gray, Katie Hunt, Amy L. Conners, Vera J. Suman, Krishna R. Kalari, James N. Ingle, Zhenkun Lou, Daniel W. Visscher, Richard Weinshilboum, Judy C. Boughey, Matthew P. Goetz, and Liewei Wang
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
An amendment to this paper has been published and can be accessed via the original article.
- Published
- 2021
- Full Text
- View/download PDF
26. The emerging role of CDK4/6i in HER2-positive breast cancer
- Author
-
Ciara C. O’Sullivan, Vera J. Suman, and Matthew P. Goetz
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Prior to the advent of the monoclonal antibody trastuzumab, human epidermal growth-factor receptor 2 (HER2)-positive (HER2+) breast cancer (BC) was associated with an aggressive clinical course and poor survival outcomes. In the era of effective HER2-directed therapies, median survival rates for patients with metastatic HER2+ BC now approach 5 years. Despite these improvements, the majority of affected patients unfortunately die from disease. Therapies to overcome treatment resistance are being actively pursued. One strategy has been to target the cyclin-dependent kinases 4/6 (CDK4/6), as they are downstream of HER2 and many of the cellular pathways driving resistance to HER2-targeted therapies, and play a key role in proliferation by controlling transition through the G1 restriction point to the S phase of the cell cycle. In this article, we review the published literature with regard to the rationale for CDK4/6-directed therapies in HER2+ BC and discuss ongoing clinical research and new challenges in the field.
- Published
- 2019
- Full Text
- View/download PDF
27. Aromatase inhibition remodels the clonal architecture of estrogen-receptor-positive breast cancers
- Author
-
Christopher A. Miller, Yevgeniy Gindin, Charles Lu, Obi L Griffith, Malachi Griffith, Dong Shen, Jeremy Hoog, Tiandao Li, David E. Larson, Mark Watson, Sherri R Davies, Kelly Hunt, Vera J. Suman, Jacqueline Snider, Thomas Walsh, Graham A. Colditz, Katherine DeSchryver, Richard K. Wilson, Elaine R. Mardis, and Matthew J. Ellis
- Subjects
Science - Abstract
Aromatase inhibitors are used to treat oestrogen-receptor-positive breast cancer. Here, the authors use genomic approaches to analyse tumours before and after neo-adjuvant treatment and find that treatment alters the clonal landscape of the tumours.
- Published
- 2016
- Full Text
- View/download PDF
28. Uterine Artery Embolization and Pregnancy. Actual and Controversial Issues of Gestation Terms and Delivery
- Author
-
Julia E. Dobrokhotova, Igor I. Grishin, Djamilya M. Ibragimova, Inessa G. Knysheva, and Vera J. Ilchenko
- Subjects
uterine fibroids ,uterine artery embolization ,pregnancy ,childbirth ,Medicine - Abstract
Background: The aim of this study was to estimate the particular qualities of pregnancy and delivery among patients after uterine artery embolization (UAE) for uterine fibroids (UF). Materials and Methods: The study included 161pregnant women. We performed a comparative analysis of pregnancy and delivery among patients after UAE, patients with UF without UAE, and healthy patients with physiological pregnancy and childbirth. Results: The frequency of complications during pregnancy and delivery among patients after UAE for UF was not significantly different from the frequency of complications among patients without UF and significantly lower than the complication rate among patients with UF without UAE. Conclusion: UAE use is a highly efficient alternative to surgical or medical treatments for UF in patients of reproductive age, which plan pregnancy.
- Published
- 2016
- Full Text
- View/download PDF
29. Reducing Challenging Behaviours among Children and Adolescents with Intellectual Disabilities in Community Settings: A Systematic Review of Interventions
- Author
-
Orla O'Regan, Yvonne Doyle, Marguerite Murray, Vera J. C. McCarthy, and Mohamad M. Saab
- Abstract
Background: Challenging behaviours are common among children and adolescents with intellectual disabilities. Such behaviours often result in poor quality of life outcomes such as physical injury, difficulties with relationships and community integration. Aim: This systematic review aimed to synthesise evidence from studies that assessed the effect of interventions used to reduce/manage challenging behaviour among children with intellectual disabilities in community settings. Methods: Studies published between January 2015 and January 2021 were sought from five electronic databases. The quality of studies was assessed, and a narrative synthesis was conducted. Results: A total of 11 studies were included which utilised various non-pharmacological interventions including multi-model interventions, microswitch technology, cognitive behavioural therapy, art, music and illustrated stories. Microswitch cluster technology was the most used intervention. Studies using pharmacological interventions were not retrieved. Results indicated that a person-centred planning approach was key to offering individualised treatment. Conclusions: The superiority of one intervention or a combination of interventions could not be determined from this review given the heterogeneity of studies. Future research is required to explore the use and effects of pharmacological interventions to compare outcomes and improve quality of care of children with intellectual disabilities.
- Published
- 2024
- Full Text
- View/download PDF
30. RESPONSABILIDAD SOCIAL UNIVERSITARIA: UNA APROXIMACIÓN AL CONCEPTO EN LA EDUCACIÓN DEL SIGLO XXI
- Author
-
Vera J. Blanco Miranda
- Subjects
sustainable ,ethics ,university social responsibility (usr) ,Commerce ,HF1-6182 ,Economics as a science ,HB71-74 - Abstract
Inequality and existing social injustice, environmental degradation, loss of ethical and moral values and the irresponsible use of scientific and technological knowledge, require us to rethink the kind of education that are offered in universities, since they are these institutions to whom society has given them the mission to train individuals responsible for transforming the world we live in more humane and sustainable one. This commitment, of the twenty-first century, it is necessary to assume from a social viewpoint not only to fulfill the undertaken of UNESCO declared the decade of 2005-2014 as the decade for education for sustainable development, but, on the urgent need to form citizens capable of responding critically and ethical commitment to economic, social, cultural, political and environmental changes caused by globalization and the knowledge society. Is required by the universities, a new commitment from his missionary functions especially the challenge of transforming their educational practices focused on rote knowledge transmission and decontextualized way to reality, educational practices that make it a university socially responsible. In this sense, and based on the review of the literature and empirical evidence, it is intended to address a theoretical approach to the concept of university social responsibility, in order to contribute to the systematization of it and identifying strategies and policies allow the humanization of education and professional forger of the country and the world needs to achieve peace, social justice, welfare, equity and sustainable human development within a framework where democratic values and rights are respected, civil, environmental and cultural.
- Published
- 2015
- Full Text
- View/download PDF
31. Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer
- Author
-
Jonathan T. Lei, Jieya Shao, Jin Zhang, Michael Iglesia, Doug W. Chan, Jin Cao, Meenakshi Anurag, Purba Singh, Xiaping He, Yoshimasa Kosaka, Ryoichi Matsunuma, Robert Crowder, Jeremy Hoog, Chanpheng Phommaly, Rodrigo Goncalves, Susana Ramalho, Raquel Mary Rodrigues Peres, Nindo Punturi, Cheryl Schmidt, Alex Bartram, Eric Jou, Vaishnavi Devarakonda, Kimberly R. Holloway, W. Victoria Lai, Oliver Hampton, Anna Rogers, Ethan Tobias, Poojan A. Parikh, Sherri R. Davies, Shunqiang Li, Cynthia X. Ma, Vera J. Suman, Kelly K. Hunt, Mark A. Watson, Katherine A. Hoadley, E. Aubrey Thompson, Xi Chen, Shyam M. Kavuri, Chad J. Creighton, Christopher A. Maher, Charles M. Perou, Svasti Haricharan, and Matthew J. Ellis
- Subjects
Biology (General) ,QH301-705.5 - Abstract
Summary: RNA sequencing (RNA-seq) detects estrogen receptor alpha gene (ESR1) fusion transcripts in estrogen receptor-positive (ER+) breast cancer, but their role in disease pathogenesis remains unclear. We examined multiple ESR1 fusions and found that two, both identified in advanced endocrine treatment-resistant disease, encoded stable and functional fusion proteins. In both examples, ESR1-e6>YAP1 and ESR1-e6>PCDH11X, ESR1 exons 1–6 were fused in frame to C-terminal sequences from the partner gene. Functional properties include estrogen-independent growth, constitutive expression of ER target genes, and anti-estrogen resistance. Both fusions activate a metastasis-associated transcriptional program, induce cellular motility, and promote the development of lung metastasis. ESR1-e6>YAP1- and ESR1-e6>PCDH11X-induced growth remained sensitive to a CDK4/6 inhibitor, and a patient-derived xenograft (PDX) naturally expressing the ESR1-e6>YAP1 fusion was also responsive. Transcriptionally active ESR1 fusions therefore trigger both endocrine therapy resistance and metastatic progression, explaining the association with fatal disease progression, although CDK4/6 inhibitor treatment is predicted to be effective. : Lei et al. show that transcriptionally active estrogen receptor gene (ESR1) fusions identified from late-stage, treatment-refractory estrogen receptor-positive (ER+) breast cancer drive pan-endocrine therapy resistance and metastatic progression. Growth of breast tumors driven by ESR1 fusions at primary and metastatic sties can be suppressed with a CDK4/6 inhibitor. Keywords: ESR1 fusions, breast cancer, endocrine therapy resistance, metastasis, EMT, PDX
- Published
- 2018
- Full Text
- View/download PDF
32. Exploring patient information needs in type 2 diabetes: A cross sectional study of questions.
- Author
-
Colleen E Crangle, Colin Bradley, Paul F Carlin, Robert J Esterhay, Roy Harper, Patricia M Kearney, Vera J C McCarthy, Michael F McTear, Eileen Savage, Mark S Tuttle, and Jonathan G Wallace
- Subjects
Medicine ,Science - Abstract
This study set out to analyze questions about type 2 diabetes mellitus (T2DM) from patients and the public. The aim was to better understand people's information needs by starting with what they do not know, discovered through their own questions, rather than starting with what we know about T2DM and subsequently finding ways to communicate that information to people affected by or at risk of the disease. One hundred and sixty-four questions were collected from 120 patients attending outpatient diabetes clinics and 300 questions from 100 members of the public through the Amazon Mechanical Turk crowdsourcing platform. Twenty-three general and diabetes-specific topics and five phases of disease progression were identified; these were used to manually categorize the questions. Analyses were performed to determine which topics, if any, were significant predictors of a question's being asked by a patient or the public, and similarly for questions from a woman or a man. Further analysis identified the individual topics that were assigned significantly more often to the crowdsourced or clinic questions. These were Causes (CI: [-0.07, -0.03], p < .001), Risk Factors ([-0.08, -0.03], p < .001), Prevention ([-0.06, -0.02], p < .001), Diagnosis ([-0.05, -0.02], p < .001), and Distribution of a Disease in a Population ([-0.05,-0.01], p = .0016) for the crowdsourced questions and Treatment ([0.03, 0.01], p = .0019), Disease Complications ([0.02, 0.07], p < .001), and Psychosocial ([0.05, 0.1], p < .001) for the clinic questions. No highly significant gender-specific topics emerged in our study, but questions about Weight were more likely to come from women and Psychosocial questions from men. There were significantly more crowdsourced questions about the time Prior to any Diagnosis ([(-0.11, -0.04], p = .0013) and significantly more clinic questions about Health Maintenance and Prevention after diagnosis ([0.07. 0.17], p < .001). A descriptive analysis pointed to the value provided by the specificity of questions, their potential to disclose emotions behind questions, and the as-yet unrecognized information needs they can reveal. Large-scale collection of questions from patients across the spectrum of T2DM progression and from the public-a significant percentage of whom are likely to be as yet undiagnosed-is expected to yield further valuable insights.
- Published
- 2018
- Full Text
- View/download PDF
33. Regulatory considerations for developing remote measurement technologies for Alzheimer’s disease research
- Author
-
Erdemli, Gül, Grammatikopoulou, Margarita, Wagner, Bertil, Vairavan, Srinivasan, Curcic, Jelena, Aarsland, Dag, Wittenberg, Gayle, Nikolopoulos, Spiros, Muurling, Marijn, Froehlich, Holger, de Boer, Casper, Shanbhag, Niraj M., Nies, Vera J. M., Coello, Neva, Gove, Dianne, Diaz, Ana, Foy, Suzanne, Dartee, Wim, and Brem, Anna-Katharine
- Published
- 2024
- Full Text
- View/download PDF
34. Pre-treatment peripheral blood immunophenotyping and response to neoadjuvant chemotherapy in operable breast cancer
- Author
-
Leon-Ferre, Roberto A., Whitaker, Kaitlyn R., Suman, Vera J., Hoskin, Tanya, Giridhar, Karthik V., Moore, Raymond M., Al-Jarrad, Ahmad, McLaughlin, Sarah A., Northfelt, Donald W., Hunt, Katie N., Conners, Amy Lynn, Moyer, Ann, Carter, Jodi M., Kalari, Krishna, Weinshilboum, Richard, Wang, Liewei, Ingle, James N., Knutson, Keith L., Ansell, Stephen M., Boughey, Judy C., Goetz, Matthew P., and Villasboas, Jose C.
- Published
- 2024
- Full Text
- View/download PDF
35. Automated mitotic spindle hotspot counts are highly associated with clinical outcomes in systemically untreated early-stage triple-negative breast cancer
- Author
-
Leon-Ferre, Roberto A., Carter, Jodi M., Zahrieh, David, Sinnwell, Jason P., Salgado, Roberto, Suman, Vera J., Hillman, David W., Boughey, Judy C., Kalari, Krishna R., Couch, Fergus J., Ingle, James N., Balkenhol, Maschenka, Ciompi, Francesco, van der Laak, Jeroen, and Goetz, Matthew P.
- Published
- 2024
- Full Text
- View/download PDF
36. Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for high-risk operable Stage III melanoma: the Phase II NeoACTIVATE trial
- Author
-
Hieken, Tina J., Nelson, Garth D., Flotte, Thomas J., Grewal, Eric P., Chen, Jun, McWilliams, Robert R., Kottschade, Lisa A., Yang, Lu, Domingo-Musibay, Evidio, Dronca, Roxana S., Yan, Yiyi, Markovic, Svetomir N., Dimou, Anastasios, Montane, Heather N., Erskine, Courtney L., Piltin, Mara A., Price, Daniel L., Khariwala, Samir S., Hui, Jane, Strand, Carrie A., Harrington, Susan M., Suman, Vera J., Dong, Haidong, and Block, Matthew S.
- Published
- 2024
- Full Text
- View/download PDF
37. Long-Term Treatment with Alcaligenes faecalis A12C Improves Host Resistance to Pathogens in Septic Rats: Possible Contribution of Curdlan-Like Immune Trainer
- Author
-
Martel-Benítez, C. J., Alayón-Afonso, R., Castillo, D. Padilla, Chamizo-López, F. J., García-Laorden, M. Isabel, de los Monteros y Zayas, A. Espinosa, Rivero-Vera, J. C., Salgueiro, P. Nogueira, Real, F., Bordes-Benítez, A., Quintana, A. Martel, Peña, C. Almeida, Cabrera, C. Domínguez, González-Martín, J. M., Caballero, J. Martín, Beneyto, R. Frías, Villar, Jesús, and Martín-Barrasa, J. L.
- Published
- 2024
- Full Text
- View/download PDF
38. Five million years of Antarctic Circumpolar Current strength variability
- Author
-
Lamy, Frank, Winckler, Gisela, Arz, Helge W., Farmer, Jesse R., Gottschalk, Julia, Lembke-Jene, Lester, Middleton, Jennifer L., van der Does, Michèlle, Tiedemann, Ralf, Alvarez Zarikian, Carlos, Basak, Chandranath, Brombacher, Anieke, Dumm, Levin, Esper, Oliver M., Herbert, Lisa C., Iwasaki, Shinya, Kreps, Gaston, Lawson, Vera J., Lo, Li, Malinverno, Elisa, Martinez-Garcia, Alfredo, Michel, Elisabeth, Moretti, Simone, Moy, Christopher M., Ravelo, Ana Christina, Riesselman, Christina R., Saavedra-Pellitero, Mariem, Sadatzki, Henrik, Seo, Inah, Singh, Raj K., Smith, Rebecca A., Souza, Alexandre L., Stoner, Joseph S., Toyos, Maria, de Oliveira, Igor M. Venancio P., Wan, Sui, Wu, Shuzhuang, and Zhao, Xiangyu
- Published
- 2024
- Full Text
- View/download PDF
39. A comprehensive analysis of breast cancer microbiota and host gene expression.
- Author
-
Kevin J Thompson, James N Ingle, Xiaojia Tang, Nicholas Chia, Patricio R Jeraldo, Marina R Walther-Antonio, Karunya K Kandimalla, Stephen Johnson, Janet Z Yao, Sean C Harrington, Vera J Suman, Liewei Wang, Richard L Weinshilboum, Judy C Boughey, Jean-Pierre Kocher, Heidi Nelson, Matthew P Goetz, and Krishna R Kalari
- Subjects
Medicine ,Science - Abstract
The inflammatory tumoral-immune response alters the physiology of the tumor microenvironment, which may attenuate genomic instability. In addition to inducing inflammatory immune responses, several pathogenic bacteria produce genotoxins. However the extent of microbial contribution to the tumor microenvironment biology remains unknown. We utilized The Cancer Genome Atlas, (TCGA) breast cancer data to perform a novel experiment utilizing unmapped and mapped RNA sequencing read evidence to minimize laboratory costs and effort. Our objective was to characterize the microbiota and associate the microbiota with the tumor expression profiles, for 668 breast tumor tissues and 72 non-cancerous adjacent tissues. The prominent presence of Proteobacteria was increased in the tumor tissues and conversely Actinobacteria abundance increase in non-cancerous adjacent tissues. Further, geneset enrichment suggests Listeria spp to be associated with the expression profiles of genes involved with epithelial to mesenchymal transitions. Moreover, evidence suggests H. influenza may reside in the surrounding stromal material and was significantly associated with the proliferative pathways: G2M checkpoint, E2F transcription factors, and mitotic spindle assembly. In summary, further unraveling this complicated interplay should enable us to better diagnose and treat breast cancer patients.
- Published
- 2017
- Full Text
- View/download PDF
40. The Use of Stem Cells to Model Amyotrophic Lateral Sclerosis and Frontotemporal Dementia: From Basic Research to Regenerative Medicine
- Author
-
Erin C. Hedges, Vera J. Mehler, and Agnes L. Nishimura
- Subjects
Internal medicine ,RC31-1245 - Abstract
In recent years several genes have linked amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) as a spectrum disease; however little is known about what triggers their onset. With the ability to generate patient specific stem cell lines from somatic cells, it is possible to model disease without the need to transfect cells with exogenous DNA. These pluripotent stem cells have opened new avenues for identification of disease phenotypes and their relation to specific molecular pathways. Thus, as never before, compounds with potential applications for regenerative medicine can be specifically tailored in patient derived cultures. In this review, we discuss how patient specific induced pluripotent stem cells (iPSCs) have been used to model ALS and FTD and the most recent drug screening targets for these diseases. We also discuss how an iPSC bank would improve the quality of the available cell lines and how it would increase knowledge about the ALS/FTD disease spectrum.
- Published
- 2016
- Full Text
- View/download PDF
41. Apoptotic Activity of MeCP2 Is Enhanced by C-Terminal Truncating Mutations.
- Author
-
Alison A Williams, Vera J Mehler, Christina Mueller, Fernando Vonhoff, Robin White, and Carsten Duch
- Subjects
Medicine ,Science - Abstract
Methyl-CpG binding protein 2 (MeCP2) is a widely abundant, multifunctional protein most highly expressed in post-mitotic neurons. Mutations causing Rett syndrome and related neurodevelopmental disorders have been identified along the entire MECP2 locus, but symptoms vary depending on mutation type and location. C-terminal mutations are prevalent, but little is known about the function of the MeCP2 C-terminus. We employ the genetic efficiency of Drosophila to provide evidence that expression of p.Arg294* (more commonly identified as R294X), a human MECP2 E2 mutant allele causing truncation of the C-terminal domains, promotes apoptosis of identified neurons in vivo. We confirm this novel finding in HEK293T cells and then use Drosophila to map the region critical for neuronal apoptosis to a small sequence at the end of the C-terminal domain. In vitro studies in mammalian systems previously indicated a role of the MeCP2 E2 isoform in apoptosis, which is facilitated by phosphorylation at serine 80 (S80) and decreased by interactions with the forkhead protein FoxG1. We confirm the roles of S80 phosphorylation and forkhead domain transcription factors in affecting MeCP2-induced apoptosis in Drosophila in vivo, thus indicating mechanistic conservation between flies and mammalian cells. Our findings are consistent with a model in which C- and N-terminal interactions are required for healthy function of MeCP2.
- Published
- 2016
- Full Text
- View/download PDF
42. Breast Cancer Risk Perceptions Among Underserved, Hispanic Women: Implications for Risk-Based Approaches to Screening
- Author
-
Austin, Jessica D., Jenkins, Sarah M., Suman, Vera J., Raygoza, Jhenitza P., Ridgeway, Jennifer L., Norman, Aaron, Gonzalez, Crystal, Hernandez, Valentina, Ghosh, Karthik, Patel, Bhavika K., and Vachon, Celine M.
- Published
- 2024
- Full Text
- View/download PDF
43. Clustering and Geodesic Scaling of Dissimilarities on the Spherical Surface
- Author
-
Fernando Vera, J., Subiabre, Ricardo, and Macías, Rodrigo
- Published
- 2024
- Full Text
- View/download PDF
44. Reliability of Dye Penetrant Inspection Method to Detect Weld Discontinuities
- Author
-
Vera, J., Caballero, L., and Taboada, M.
- Published
- 2024
- Full Text
- View/download PDF
45. An MDS-based unifying approach to time series K-means clustering: application in the dynamic time warping framework
- Author
-
Vera, J. Fernando and Angulo, José M.
- Published
- 2023
- Full Text
- View/download PDF
46. Investigation of Dynamic Behaviour of Receptor Tyrosine Kinase and Protein Tyrosine Phospatase Reaction Network using Mathematical Model
- Author
-
Wolkenhauer O., Petrov V., Vera J., and Nikolov S.
- Subjects
PTP-RTK Reaction Network ,Mathematical Model ,Bifurcation Analysis ,Biotechnology ,TP248.13-248.65 ,Biology (General) ,QH301-705.5 - Abstract
The dynamic and bifurcation behaviour of receptor tyrosin kinase (RTK) and protein tyrosine phospatase (PTP) reaction network model is investigated on the basis of Lyapunov-Andronov's theory. According to our qualitative and bifurcation analysis, propagation of phosphorylation is only possible in the unstable regime of the reaction network, i.e. when kinase activity of the receptor increases on phosphorylation. For some values of the model parameters first Lyapunov value can be positive or negative and bistability takes place.
- Published
- 2007
47. Targeting TAG-72 in cutaneous T cell lymphoma
- Author
-
Evtimov, Vera J., Hammett, Maree V., Pupovac, Aleta, Nguyen, Nhu-Y N., Shu, Runzhe, Van Der Weyden, Carrie, Twigger, Robert, Nisbet, Ian T., Trounson, Alan O., Boyd, Richard L., and Prince, H. Miles
- Published
- 2024
- Full Text
- View/download PDF
48. Recent deep-sea nematodes and agglutinated foraminifera select specific grains and bioclasts from their environments: Ecological implications
- Author
-
Das, Sunil K., Singh, Raj K., Saavedra-Pellitero, Mariem, Gottschalk, Julia, Alvarez Zarikian, Carlos A., Lembke-Jene, Lester, Lamy, Frank, Winckler, Gisela, Middleton, Jennifer L., Arz, Helge W., Basak, Chandranath, Brombacher, Anieke, Esper, Oliver M., Farmer, Jesse R., Herbert, Lisa C., Iwasaki, Shinya, Lawson, Vera J., Lo, Li, Malinverno, Elisa, Michel, Elisabeth, Moretti, Simone, Moy, Christopher M., Ravelo, Ana Christina, Riesselman, Christina R., Seo, Inah, Smith, Rebecca A., Souza, Alexandre L., Stoner, Joseph S., Venancio, Igor M., Wan, Sui, and Zhao, Xiangyu
- Published
- 2024
- Full Text
- View/download PDF
49. Comparison of diabetes risk score estimates and cardiometabolic risk profiles in a middle-aged Irish population.
- Author
-
Catherine M Phillips, Patricia M Kearney, Vera J McCarthy, Janas M Harrington, Anthony P Fitzgerald, and Ivan J Perry
- Subjects
Medicine ,Science - Abstract
BackgroundTo compare diabetes risk assessment tools in estimating risk of developing type 2 diabetes (T2DM) and to evaluate cardiometabolic risk profiles in a middle-aged Irish population.MethodsFuture risk of developing T2DM was estimated using 7 risk scores, including clinical measures with or without anthropometric, biological and lifestyle data, in the cross-sectional Mitchelstown cohort of 2,047 middle-aged men and women. Cardiometabolic phenotypes including markers of glucose metabolism, inflammatory and lipid profiles were determined.ResultsEstimates of subjects at risk for developing T2DM varied considerably according to the risk assessment tool used (0.3% to 20%), with higher proportions of males at risk (0-29.2% vs. 0.1-13.4%, for men and women, respectively). Extrapolated to the Irish population of similar age, the overall number of adults at high risk of developing T2DM ranges from 3,378 to 236,632. Numbers of non-optimal metabolic features were generally greater among those at high risk of developing T2DM. However, cardiometabolic profile characterisation revealed that only those classified at high risk by the Griffin (UK Cambridge) score displayed a more pro-inflammatory, obese, hypertensive, dysglycaemic and insulin resistant metabolic phenotype.ConclusionsMost diabetes risk scores examined offer limited ability to identify subjects with metabolic abnormalities and at risk of developing T2DM. Our results highlight the need to validate diabetes risk scoring tools for each population studied and the potential for developing an Irish diabetes risk score, which may help to promote self awareness and identify high risk individuals and diabetes hot spots for targeted public health interventions.
- Published
- 2013
- Full Text
- View/download PDF
50. Defining metabolically healthy obesity: role of dietary and lifestyle factors.
- Author
-
Catherine M Phillips, Christina Dillon, Janas M Harrington, Vera J C McCarthy, Patricia M Kearney, Anthony P Fitzgerald, and Ivan J Perry
- Subjects
Medicine ,Science - Abstract
BACKGROUND:There is a current lack of consensus on defining metabolically healthy obesity (MHO). Limited data on dietary and lifestyle factors and MHO exist. The aim of this study is to compare the prevalence, dietary factors and lifestyle behaviours of metabolically healthy and unhealthy obese and non-obese subjects according to different metabolic health criteria. METHOD:Cross-sectional sample of 1,008 men and 1,039 women aged 45-74 years participated in the study. Participants were classified as obese (BMI ≥ 30 kg/m(2)) and non-obese (BMI < 30 kg/m(2)). Metabolic health status was defined using five existing MH definitions based on a range of cardiometabolic abnormalities. Dietary composition and quality, food pyramid servings, physical activity, alcohol and smoking behaviours were examined. RESULTS:The prevalence of MHO varied considerably between definitions (2.2% to 11.9%), was higher among females and generally increased with age. Agreement between MHO classifications was poor. Among the obese, prevalence of MH was 6.8% to 36.6%. Among the non-obese, prevalence of metabolically unhealthy subjects was 21.8% to 87%. Calorie intake, dietary macronutrient composition, physical activity, alcohol and smoking behaviours were similar between the metabolically healthy and unhealthy regardless of BMI. Greater compliance with food pyramid recommendations and higher dietary quality were positively associated with metabolic health in obese (OR 1.45-1.53 unadjusted model) and non-obese subjects (OR 1.37-1.39 unadjusted model), respectively. Physical activity was associated with MHO defined by insulin resistance (OR 1.87, 95% CI 1.19-2.92, p = 0.006). CONCLUSION:A standard MHO definition is required. Moderate and high levels of physical activity and compliance with food pyramid recommendations increase the likelihood of MHO. Stratification of obese individuals based on their metabolic health phenotype may be important in ascertaining the appropriate therapeutic or intervention strategy.
- Published
- 2013
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.